UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.
Health care workers at the University of Illinois Hospital and Health Sciences System, or UI Health, are participating in a national registry of frontline workers during the COVID-19 pandemic. The HERO Registry seeks to engage health care workers, understand their experiences and track health outcomes — from COVID-19 infection to stress and burnout.
A study explored racial inequalities in death from liver cancer before and after the introduction of lifesaving drugs for hepatitis C. Results showed that from 1979 to 1998, racial inequalities in mortality from liver cancer in the U.S. were declining. But, from 1998 to 2016, of the 16,770 deaths from liver cancer among blacks, the excess relative to whites increased from 27.8 percent to 45.4 percent. Concurrently, racial inequalities in death decreased for major risk factors for liver cancer, such as alcohol and diabetes.
Rates of alcohol use disorder (AUD) have risen in the US in recent years. A small number of pharmacotherapies (drug treatments) are available for AUD, but there is an urgent need for more treatments to be evaluated. Increasingly, novel medications, as well as behavioral interventions, are tested in laboratory-based studies, where the impact on participants’ alcohol consumption can be directly assessed. However, it is not known if drinking in the laboratory setting accurately reflects individuals’ real-life drinking behavior and therefore if study findings hold true in the real-world. A new report in the journal Alcoholism: Clinical and Experimental Research by researchers from the NIAAA-supported Center for the Translational Neuroscience of Alcoholism at Yale University addresses this issue, by examining the extent to which individuals’ drinking in a laboratory setting correlates with their (self-reported) alcohol use in the lead-up to the study.
Using an ultra-thin and sharp needle tipped with a single carbon monoxide molecule frozen to minus 266 degrees centigrade, researchers from the University of Warwick and Cardiff identified and mapped the location of every molecular bond on the surface of a material
Strategies that treat households in the broad vicinity of a recent malaria case with anti-malarial drugs, insecticides, or both could significantly reduce malaria in low-transmission settings.
UC San Diego Health has launched a Phase III clinical trial to assess whether a medication used to treat rheumatoid might also have therapeutic value for patient with COVID-19 who have developed or are at high risk of developing serious lung damage from SARS-CoV-2 infections.
Aggressive forms of prostate cancer don’t act the way they should, hanging on to genetic materials called introns that should be thrown away, researchers from Roswell Park reported today in Nature Communications.
Research by University of Iowa virologist Wendy Maury, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.
Researchers at Montefiore Health System and Albert Einstein College of Medicine have begun testing the drug hydroxychloroquine for the treatment of COVID-19, as part of a nationwide trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI).
A new survey of U.S. primary care physicians from researchers at Johns Hopkins Bloomberg School of Public Health found that nearly one-third, 32.9 percent, do not think treating opioid use disorder with medication is any more effective than treatment without medication.
The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.
University of Colorado Cancer Center study of early-phase clinical trials finds variations in reporting of drug side effects, potentially obscuring safety.
A new study led by University of Kentucky researcher April Young and Emory University researcher Hannah Cooper shows that a number of pharmacies in the Appalachian region of Kentucky are limiting the dispensing of buprenorphine, a medication used to treat opioid use disorder (OUD).
While lifesaving to cancer patients, chemotherapy drugs can be hazardous for the health care workers who handle them, especially during a spill. Inconsistent use of personal protective equipment when cleaning up a spill and problems with closed-system transfer devices — which are designed to prevent the release of toxic vapors and liquids — topped issues uncovered by a new safety study involving nearly 400 nurses across 12 academic infusion centers.
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing the effectiveness of hydroxychloroquine as a therapy to prevent infection and symptoms in individuals who have been exposed to COVID-19-positive individuals. The trial is significant because it focuses on preventing COVID-19 and does not involve individuals who are ill with infection but rather healthy individuals who have been exposed.
Fermilab, Brookhaven, and Open Science Grid dedicate computational power to COVID-19 research.
Antibiotic treatment — which depletes gut microbes — drastically changes the parts of a rat’s brain that are activated during opioid addiction and withdrawal.
The advance has the potential to eliminate complications that arise from missing doses of life-saving medicines, according to the study published today in Nature Materials, a leading peer-reviewed biomedical research journal.
Results from a new mouse study suggest that a new light-activated drug delivery method helps confine treatments to the joints, which could reduce whole-body side effects.
Researchers have discovered a common molecular pathway in women who experience preterm labor and are using this insight to develop new treatments for woman who experience early labor.
Scientists have identified a collection of biomarkers that together signal that a person’s cancer treatment may be harming their heart.
A research team led by Professor Dean Ho from the National University of Singapore has developed a ground-breaking artificial intelligence platform known as ‘IDentif.AI’ which can identify optimal drug combination therapies at unprecedented speeds.
Public health expert, John C. Licciardone, a physician and preventive medicine specialist, discusses the potential impact of COVID-19 on patients' access to recommended treatments for chronic pain.
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced today the program and speakers for Virtual ISPOR 2020.
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
Researchers are now enrolling outpatients with COVID-19 for a randomized controlled trial of the effectiveness of two drug regimens – hydroxychloroquine and hydroxychloroquine with azithromycin. There is conflicting evidence on whether it works, which is why the research team at the University of Washington School of Medicine is conducting a rigorous trial to offer answers.
患有心脏病和其他基础疾病的人士如果感染COVID-19，可能有发展为重症的高风险。有关这种新型病毒性疾病，目前发表的研究很少，心脏病患者可能会不确定他们是否为保持健康采取正确的做法。为此，Mayo Clinic的心脏病科医生、医学博士Stephen Kopecky就心脏病患者在COVID-19疫情期间需要注意哪些事情发表了看法。
Quienes padecen enfermedades cardíacas y otras afecciones corren más riesgo de enfermar gravemente si llegan a desarrollar la COVID-19. Por ello, los pacientes cardíacos posiblemente se pregunten si están haciendo lo correcto para su salud en este momento, cuando hay pocos estudios respecto a esta nueva enfermedad viral.
El SARS-CoV-2 o virus que causa la COVID-19 continúa propagándose y ha llevado a más de 20 000 muertes en todo el mundo en menos de 4 meses. Los esfuerzos por desarrollar una vacuna contra la COVID-19 avanzan, pero todavía parece improbable tenerla antes de 12 o 18 meses.
المصابون بأمراض القلب والحالات الصحية الكامنة الأخرى أكثر عرضة للمرض الخطير إذا أصيبوا بفيروس كورونا المستجد (كوفيد-19). قد يتساءل مرضى القلب عما إذا كانوا يفعلون ما يجب من أجل صحتهم، في وقت لا يتوفر فيه عن هذا المرض الفيروسي الجديد إلا القليل من الأبحاث.
Pessoas com doença cardíaca e outros problemas de saúde subjacentes correm o risco de ficarem gravemente doentes se contraírem a COVID-19. Pacientes cardíacos podem questionar se estão fazendo as coisas certas para sua saúde em um momento em que há poucas pesquisas disponíveis a respeito dessa nova doença viral.
O SARS-CoV-2, o vírus que causa o COVID-19, continua a se espalhar, levando a mais de 20.000 mortes em todo o mundo em menos de quatro meses. Esforços estão progredindo para desenvolver uma vacina para o COVID-19, mas é provável que isso ainda leve de 12 a 18 meses.
يواصل فيروس كورونا (SARS-CoV-2)، الفيروس الذي يسبب فيروس كورونا المستجد (كوفيد-19)، وتيرة انتشاره مسببًا أكثر من 20,000 حالة وفاة حول العالم في أقل من أربعة شهور. ولا تزال الجهود لتطوير لقاح لفيروس كورونا المستجد (كوفيد-19) قائمة، ولكن يُحتمل أن تستغرق ما بين 12 إلى 18 شهرًا.
The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial. Data will be shared virtually at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.
The researchers discovered that encapsulating ellagic acid in chitosan, a sugar, reduces its inherent cytotoxicity while enhancing its anti-oxidant properties. The chitosan shell, which makes up the hard outer skeleton of shellfish, also permits EA delivery via a rapid burst phase and a relatively slow phase.
The University of Alabama at Birmingham will join an international effort coordinated by Scripps Research to test drugs for COVID-19. The work centers around ReFRAME, a vast collection of drugs developed for other diseases that are already known to be safe for humans.
Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently. Results from the dose-finding study were published April 23 in JAMA Ophthalmology. The study was conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and supported by the National Eye Institute (NEI), part of the National Institutes of Health.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
Researchers from the University of British Columbia studied three lidocaine derivatives for use as motor blockade with promising results. This study provides insight into developing more effective, longer-lasting non-opioid local anesthetics, which could improve postoperative pain control. ASRA presented researchers with "Best of Meeting Abstract" and "Resident/Fellow Travel Award" for their work.
The sooner hip replacement patients can walk after surgery, the faster they can be discharged, allowing for more comfortable recovery at home, lower overall cost of care, and increased availability of critical hospital resources. Results of a recent study found that patients who received mepivacaine spinal anesthesia were more likely to ambulate early and be discharged on the day of surgery.
Using an erector spinae plane block (ESPB) for postoperative analgesia from total shoulder replacement offers advantages over the more commonly used interscalene brachial plexus nerve block, including avoiding phrenic nerve complications and upper-extremity mobility issues, researchers from Stanford University in Stanford, CA, reported in findings from a new study.
The Pathogen and Microbiome Institute (PMI) at Northern Arizona University (NAU) today announced that it is launching the COVID-19 Testing Service Center (CTSC) to grow the SARS-CoV-2 virus and test new drugs against it. By repurposing its existing biodefense research infrastructure for the new testing facility—labs rated at Biosafety Level 3 (BSL-3), one of the highest levels of biocontainment—PMI is dedicating much of its significant research capacity to fight the COVID-19 pandemic.
Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.
When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.
UT Southwestern Medical Center scientists have discovered a protein that works with others during development to put the brakes on cell division in the heart, they report today in Nature.
Study: with smaller clinical trials, it may be up to doctors to notice rare drug side effects
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right